1. Healthcare

Registration form
th
XIII Annual Conference on
Evidence Based Management of Cancers
In India
Name on Certificate/Badge:_______________________________
Tata Memorial Centre
Institute: _____________________________________________
_____________________________________________________
Department: __________________________________________
Medical Council Registration Number: ______________________
Address for Correspondence: _____________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
XIIIth Annual Conference
on
Evidence Based Management
of Cancers In India
Pin Code ______________________________________________
E-mail: _______________________________________________
Tel No: _______________________________________________
Mobile No: ____________________________________________
Registration fees:
3 Days
2 Day
1 Day/
Work shop
Early bird (upto 31st January 2015) Rs. 4000 Rs. 2500 Rs. 1500
From 1st Feb to 20th Feb 2015
Rs. 5500 Rs. 3500 Rs. 2000
SAARC & International
Rs. 7000 Rs. 4500 Rs. 2500
Spot Registration
Rs. 7000 Rs. 4500 Rs. 2500
*Junior Residents (upto 21st Feb)
Rs. 2000 Rs. 1500 Rs. 1000
*Junior Residents (Spot Regn)
Rs. 2500 Rs. 2000 Rs. 1250
Registration fees may be paid online or by DD/Cheque drawn in favor of
“TMH EBM”
(please add Rs 80 for outstation cheques)
Registration will not be accepted from 23rd – 26th Feb 2015.
*with letter of support from Head of the Department/Institute
For Registration & other details, please contact:
Ms. Meenakshi / Ms. Shraddha
Clinical Research Secretariat (CRS) and DAE-CTC
rd
3 Floor Main Building,
Tata Memorial Hospital,
Parel, Mumbai 400012,India
Tel: +91-22-24177000; Extn 4254 / Fax: +91-22-24168604
E-mail: [email protected]
Web: https://tmc.gov.in/newsnevents/event-list.htm
Molecular Haematology :
Laboratory Testing for
Myeloid Malignancies
27th Feb - 1st March 2015
Venue :
Prof R D Choksi Auditorium, Tata Memorial Hospital , Mumbai
Organized by :
Tata Memorial Centre, Mumbai
Clinical Research Secretariat (CRS) and
Department of Atomic Energy Clinical Trials Centre ( DAE- CTC)
XIIIth Annual Conference on
Evidence Based Management of Cancers in India
Dear All
The Tata Memorial Centre cordially invites you to the 13th conference
on “Evidence Based Management of Cancers in India- EBM 2015” to
be held from 27th February to 1st March 2015. This three day meeting
will merge with the “Hospital Day Celebration” which will
be held on 28th Feb. 2015. The Tata Memorial Hospital has pioneered
the cause of EBM in Oncology in India and has been conducting the
annual meeting on EBM in cancers for the past twelve years.
Each year we have focused on different aspect of cancer care;
collated and published the best available evidence in the form of
“EBM book” which is available on our website. This meeting helps
busy clinicians from all over the country and abroad to get updated on
the best available evidence in oncology to potentially improve
patient care. This year we will be focusing on Modern practices in
Radiation Oncology, Molecular Haematology and Cardio – Oncology.
Renowned international and national faculty members will cover the
above topics in a very focused and succinct manner. The target
audience for the meeting is radiation oncologist, pathologists,
hematooncologists, physicians, medical, surgical oncologist, basic
scientist, researchers and residents training in any of the specialties.
We look forward to welcoming you at this annual event.
Prof R A Badwe,
Director, Tata Memorial Centre
Organizing Chairman : Dr Sumeet Gujral
Organizing Secretaries : Dr Nikhil Patkar, Dr PG Subramanian
Organizing Committee : Dr Prashant Tembhare, Dr Syed Hasan
Khizer
International Faculty:
Ÿ Dr Francesco Lo Coco (University Tor Vergata of Roma, Italy)
Ÿ Dr Christian Thiede (University Hospital Dresden, Germany)
Ÿ Dr Simona Soverini (University of Bologna Italy)
Ÿ Dr David Grimwade (Kings College, London, UK)
Molecular Haematology : Laboratory Testing for
Myeloid Malignancies
Hematology has always been at the forefrontof identifying the genetic
basis of diseases including cancers. Today, medical oncologists and
hematologists rely heavily upon molecular information for routine
management of haematolgical malignancies. As a result of this
encouraging scenario the last few years have seen increasing evidence
that has addressed laboratory issues pertaining to molecular
haematology such as appropriate testing, optimal time points for
testing, assay setup for diagnosis and monitoring, criteria for analysis
and reporting of generated data. Today, we have data not just on when
to suspect resistance to tyrosine kinase inhibitors (TKI) but also on the
methodology to test for resistance and identify TKI mutations that are
clinically relevant. We also know that it is of paramount importance to
test for structural abnormalities as well as acquired somatic mutations
in acute myeloid leukemia. However, even in today's era of targeted
therapies, there is no such literature from India, which has addressed
diagnostic and monitoring methodologies and interpretation of
molecular results.
The goal of this meeting is to review current evidence and formulate
guidelines for molecular testing in hematological malignancies with a
focus on the common myeloid neoplasms such as chronic myeloid
leukemia, acute myeloid leukemia and acute promyelocytic leukemia.
This meeting will be the first of its kind in India to address laboratory
issues pertaining to testing and interpretation of molecular knowledge
and will include national and international experts. We expect to
generate evidence-based algorithms for molecular& cytogenetic
testing which shall be easily applicable in Indian setting. We also have a
one-day workshop covering basics of molecular diagnostics that will be
conducted by international and national speakers
Program Highlights
EBM 2015 (27th, 28th February 2015)
Ÿ Cytogenetic testing in chronic myeloid leukemia – Where do we
stand?
Ÿ Diagnosis and molecular monitoring of Chronic Myeloid Leukemia Current evidence on methodology, reporting and frequency of
testing.
Ÿ Testing for kinase domain mutations and resistance to Tyrosine
Kinase Inhibitors in Chronic Myeloid Leukemia -Current evidence
Ÿ Current evidence for diagnosis and monitoring of acute
promyelocytic leukemia
Ÿ What is the current evidence for cytogenetic testing in Acute
Myeloid Leukemia?
Ÿ Current evidence for molecular testing in intermediate risk AML Which genes are essential?
WORKSHOP (1st March 2015)
Workshop on assay setup, standardization and validation in molecular
diagnostics – Focus: Molecular Haematology